← Back to Patent Explorer
US4920194A Expired / Lapsed US ⏱️ 0.0 years remaining

Blood substitute

Assignee: B Braun Melsungen AG
•
Filing: 1987-10-19
•
Granted: 1990-04-24
•
Expires: 2007-10-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to stroma-free blood substitutes, which are characterized in that fragments, prepared in a per se known manner, of sulfated glycosaminoglycans are covalently linked with hemoglobin to form products the oxygen binding property of which may be adjusted to be within the range of from 2.66 kPa (20 mmHg) to 10.66 kPa (80 mmHg), and preferably to within the range of from 4.79 kPa (36 mmHg) to 9.33 kPa (70 mmHg) by pre-determining the ratio of hemoglobin to glycosaminoglycan fragment, and to a process for preparing blood substitutes.

Inventors

  • 👤 Wolfgang Feller
  • 👤 Norbert Macht
  • 👤 Johannes G. Bottrich

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 21:44
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/795; C07K14/805; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 59 words
A stroma-free blood substitute consisting essentially of an aqueous medium containing the covalently linked adducts of sulfated glycosaminoglycan fragments having molecular weights from 1000 to 10,000 daltons with hemoglobin, the proportion of said fragments and of said hemoglobin being such that the oxygen binding property of said adducts is from 4.79 kPa to 9.33 kPa partial pressure of oxygen.
Claim 2
Dependent Claim 59 words
A stroma-free blood substitute consisting essentially of an aqueous medium containing the covalently linked adducts of sulfated glycosaminoglycan fragments having molecular weights from 1000 to 10,000 daltons with hemoglobin, the proportion of said fragments and of said hemoglobin being such that the oxygen binding property of said adducts is from 4.79 kPa to 9.33 kPa partial pressure of oxygen.
Claim 3
Dependent Claim 26 words
A stroma-free blood substitute as claimed in claim 1 in which said oxygen binding property is from 5.32 kPa to 7.98 kPa partial pressure of oxygen.
Claim 4
Dependent Claim 35 words
A stroma-free blood substitute as claimed in claim 1 or 2 in which said fragments are selected from the group consisting of fragments of heparin, heparinoid, dermatan sulfate, heparin sulfate, sulfated chitin or sulfated chitosan.
Claim 5
Dependent Claim 19 words
A stroma-free blood substitute as claimed in claim 1 or 2 in which said fragments are fragments of heparin.
Claim 6
Dependent Claim 20 words
A stroma-free blood substitute as claimed in claim 4 in which said fragments are made by degrading heparin with nitrate.
Claim 7
Dependent Claim 47 words
A stroma-free blood substitute as claimed in claim 4 in which the molar ratio of hemoglobin to fragments of heparin is from 1:0.4 to 1:5 based of an assumed molecular weight of hemoglobin of 64,500 daltons and an assumed molecular weight of heparin fragments of 2000 daltons.
Claim 8
Dependent Claim 24 words
A stroma-free blood substitute as claimed in claim 4 in which the mass ratio of heparin fragments to hemoglobin is from 1:7 to 1:84.
Claim 9
Dependent Claim 64 words
A stroma-free blood substitute as claimed in claim 5 in which said heparin fragments are obtained by degradation of heparin and contain an aldehyde group, and the molar ratio of hemoglobin to aldehyde content of said fragments is from 1:0.4 to 1:5 based on an assumed molecular weight of hemoglobin of 64,500 daltons and an assumed aldehyde content of 0.5 mmol/mg of heparin fragments.
Claim 10
Dependent Claim 66 words
Process for preparing a blood substitute as claimed in claim 1 comprising mixing said glycosaminoglycan fragments in an aqueous medium at pH 5.5 to 8.5 containing 0.5 to 40% by weight of oxygenated or deoxygenated hemoglobin at a temperature from 2° to 60° C. to cause a reaction between said fragments and said hemoglobin, and diafiltering said mixture against a buffer at pH 7.1 to 7.8.
Claim 11
Dependent Claim 43 words
Process as claimed in claim 9 in which said hemoglobin is deoxygenated hemoglobin, said aqueous medium is at pH 7.1 to 7.8, the concentration of said hemoglobin is from 5 to 9% by weight, and said temperature is from 10° to 30° C.
Claim 12
Dependent Claim 18 words
Process as claimed in claim 10 in which said reaction is carried out in the absence of oxygen.
Claim 13
Dependent Claim 29 words
Process as claimed in claim 9, 10 or 11 in which said aqueous solution contains a buffer and the concentration of buffering ions is from 0.05 to 1 molar.
Claim 14
Dependent Claim 72 words
Process as claimed in claim 9, 10 or 11 in which said fragments are fragments of heparin and are incubated in a buffered aqueous medium isotonic to erythrocytes and containing intact erythrocytes, the molar ratio of hemoglobin in said erythrocytes to said fragments of heparin being from 1:0.4 to 1:20 based on an assumed molecular weight of hemoglobin of 64,500 daltons and an assumed molecular weight of heparin fragment of 2000 daltons.
Claim 15
Dependent Claim 30 words
Process as claimed in claim 9, 10 or 11 including the additional step of reducing the reaction products of said fragments and said hemoglobin by the addition of sodium borohydride.
Claim 16
Dependent Claim 32 words
Process as claimed in claim 9, 10 or 11 including the additional step of cross-linking the reaction products of said fragments and said hemoglobin by the addition of a polyfunctional cross-linking agent
Claim 17
Dependent Claim 13 words
Process as claimed in claim 15 in which said cross-linking agent is glutardialdehyde.
Claim 18
Dependent Claim 47 words
A stroma-free blood substitute as claimed in claim 5 in which the molar ratio of hemoglobin to fragments of heparin is from 1:0.4 to 1:5 based on an assumed molecular weight of hemoglobin of 64,500 daltons and an assumed molecular weight of heparin fragments of 2000 daltons.
Claim 19
Dependent Claim 24 words
A stroma-free blood substitute as claimed in claim 5 in which the mass ratio of heparin fragments to hemoglobin is from 1:7 to 1:84.

References Cited (Backward Citations)

US4001401A Cited
US4061736A Cited
US4001200A Cited
US4401652A Cited
US4547490A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-04-23 1993-10-23 1994-04-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-04-23 1997-10-23 1998-04-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-04-23 2001-10-23 2002-04-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag